Somatuline Autogel: Acromegaly Self/Partner Injection Study
Completed
Ipsen
Phase 4
2004-02-01
The purpose of this study is to allow patients with acromegaly, or their partners, to learn
how to successfully inject Somatuline Autogel at home. Ability to perform unsupervised
injections whilst maintaining adequate disease control will be assessed.
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Completed
Ipsen
Phase 4
2004-06-01
The purpose of this study is to assess the efficacy, safety and patient acceptability of
Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
Terminated
Ipsen
Phase 2
2006-01-01
The main purpose of this study is to evaluate the efficacy and safety of 3 doses of
Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and
extraocular muscular contraction in patients with active thyroid-associated ophthalmopathy of
moderate intensity.
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
Completed
Ipsen
Phase 3
2005-01-01
A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy
and safety of different dose-intervals of Lanreotide Autogel 120mg according to international
standards and compared to previous treatment with Octreotide LAR 10, 20 or 30 mg.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
